MOLECULAR STUDY OF TRANFORMING GENES IN MURINE LYMPHOMAS

最初的研究表明，胸腺淋巴瘤诱导的DNA， (AKR经化学致癌物或放射治疗的F1小鼠中含有 激活的N-ras或激活的K-ras癌基因。 几 将对同样处理的小鼠品系进行致癌基因激活调查 利用DNA介导的基因转移技术，在两个试验中：（1）在一个 筛选ras癌基因的体外试验和（2）利用 裸鼠来筛选新的致癌基因。 TL的异常表达 这些肿瘤上的抗原先于明显疾病的发展， 用于追踪和分离经治疗的胸腺细胞亚群 小鼠在潜伏期。 正常人和白血病细胞的免疫组化 组织将用于检测ras基因产物（p21）的表达 蛋白），并确定ras和TL基因之间的时间关系 在肿瘤发展的潜伏期表达。 胸腺瘤将是 分析染色体异常，特别是15三体， 确定特定染色体变化与 基因表达。 这些研究应该进一步加深我们对 参与恶性过程的基因以及它们可能在什么阶段起作用。

Initial studies have shown that DNAs from thymic lymphomas induced in (AKR\X RF)F1 mice by chemical carcinogen or radiation treatment contain activated N-ras or activated K-ras oncogenes, respectively. Several strains of mice treated similarly will be surveyed for oncogene activation using the technique of DNA-mediated gene transfer in two assays: (1) an in vitro assay to screen for ras oncogenes and (2) an in vivo assay utilizing nude mice to screen for new oncogenes. The anomalous expression of TL antigen on these tumors precedes the development of overt disease and will be used to follow and fractionate subpopulations of thymocytes from treated mice during the latent period. Immunohistochemistry of normal and leukemic tissue will be used to detect the expression of the ras gene product (p21 protein) and to determine the temporal relationship between ras and TL gene expression during the latent period of tumor development. Thymomas will be analyzed for chromosomal abnormalities, particularly trisomy 15, to identify correlations between specific chromosome changes and changes in gene expression. These studies should further our understanding about the genes involved in the malignant process and at what stages they may act.